Name | Ranirestat |
Synonyms | SX-3201 AS 3201 AS-3201 SX-3201 Ranirestat Ranirestat,AS-3201 (3R)-2'-(4-Bromo-2-fluorobenzyl)spiro[pyrrolidine-3,4'-1'H-pyrrolo[1,2-a]pyrazine]-1',2,3',5(2'H)-tetraone (R)-2'-(4-BROMO-2-FLUOROBENZYL)-1'H-SPIRO[PYRROLIDINE-3,4'-PYRROLO[1,2-A]PYRAZINE]-1',2,3',5(3'H)-TETRAONE Spiro[pyrrolidine-3,4'(1'H)-pyrrolo[1,2-a]pyrazine]-1',2,3',5(2'H)-tetrone,2'-[(4-broMo-2-fluorophenyl)Methyl]-, (3R)- |
CAS | 147254-64-6 |
Molecular Formula | C17H11BrFN3O4 |
Molar Mass | 420.19 |
Density | 1.83 |
Melting Point | 192-193℃ |
Boling Point | 702.7±60.0 °C(Predicted) |
Solubility | 10 mM in DMSO |
pKa | 10.48±0.20(Predicted) |
Storage Condition | Sealed in dry,Store in freezer, under -20°C |
In vitro study | Ranirestat concentration-dependently inhibits sorbitol accumulation in rat erythrocytes and sciatic nerves incubated in the high concentration (500 mg/dl) of glucose. The potency of Ranirestat inhibition of sorbitol accumulation is similar between rat erythrocytes and sciatic nerves with IC 50 values of 0.010 μM and 0.041 μM, respectively. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.38 ml | 11.899 ml | 23.799 ml |
5 mM | 0.476 ml | 2.38 ml | 4.76 ml |
10 mM | 0.238 ml | 1.19 ml | 2.38 ml |
5 mM | 0.048 ml | 0.238 ml | 0.476 ml |